- Staat
- TX
- Alter
- 25,0
- Geschlecht
- M
- Eingang
- 11.09.2021
- Impfdatum
- 10.09.2021
- Beginn
- 10.09.2021
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Asthenia
Electrocardiogram normal
Fall
Feeling abnormal
Syncope
Tremor
Symptomtext
Patient started feeling not good after 15+minutes administration, while sitting on a chair patient becoming weak, slided down slowly to the floor, and breifly fainted. Had him lay down with emergency spine position, and immediately took his vital sign (100/52) while had technician call 911 for paramedics. Small alcohol pad was opened to had him hold and put it close to his nose breiefly. Patient was conscious yet slightly shaking. He could answer all the questions without problems such as if he's diabetic or not. He is not diabetic, no medical history/condition yet did not eat meals nor drink water for the morning and/up till vaccination time. He insisted that he's fine and did not want us to call 911. Paramedics arrived shortly and took over for through examination. By then he was back to normal and his vital sign was back to 120/70. Paramedic highly recommended him to follow up with a doctor to see what's going on as he insisted that he did not go to ER/hospital/check in.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Syncope
- Hospital-Tage
- -
- Labordaten
- At the time of slightly fainting BP 100/52, by the time Paramedics released him BP back to 120/70. EKG taken by Paramedics shows no sign of abnormal. Paramdics concluded that his reaction to the vaccine was either due to the anxiety/fear/nervousness or skipping meals, not eating anything nor drinking water/liquid prior to administration.
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- None
- Andere Medikamente
- None
- Allergien
- None
- Vorherige Impfungen
- -
- Staat
- OH
- Alter
- 43,0
- Geschlecht
- F
- Eingang
- 06.09.2022
- Impfdatum
- 02.09.2022
- Beginn
- 02.09.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: ja
Erholt: ja
Abdominal discomfort
Chest pain
Dizziness
Dyspepsia
Dysphonia
Eructation
Flatulence
Flushing
Heart rate decreased
Hypoaesthesia
Pruritus
Somnolence
X-ray
Symptomtext
Pt returns to xray complaining of left arm numbness, left facial numbness, flushing, and pruritis. Pt states she feels dizzy and like she may pass out. Pt placed in seated position and given cold compress. Pt given 25mg Benadryl at 17:15. Itching starts to subside. Pt's oxygen is staying between 97-99%. Heart rate stayed steady in the 90s. Pt denies SOB and chest pain. Pt is in no acute distress. Provider and/or nurse in room with patient for first 20 minutes of allergic reaction. No angioedema present. Patient's face and arms are flushed. No respiratory compromise, new wheezing, sore throat, or SOB. Pt voices numbness has stopped after 10 minutes. Pt denies previous allergic reactions to any prior vaccinations. Voices she is allergic only to latex and grapefruit. She did get itchy with the COVID vaccine but not to this extent. 17:45 pt is given 25mg Benadryl, 20mg Pepcid, and 80mg IM methylprednisolone. Pt continues to deny chest pain and SOB. Oxygen stays at 99%. Heart decreases into the 80s and stays stable. Pt is checked every 5 minutes. Pt informed she will be held for observation for 30 minutes. 1815 Pt reports symptoms have subsided. Denies current itching, numbness or dizziness. Voices drowsiness and heartburn. Flushing has also subsided. Reports she has a "gas" feeling in her stomach. Pt given option to be seen in ED for heartburn/chest pain. Pt declines ED. She reports she is "belching a lot" and denies chest pain. Pt's husband enters the building. He drove her to her appt today. Pt and husband given strict ED precautions including SOB, chest pain, pt not acting herself, new numbness and weakness, and return of previous symptoms. Prednisone sent to pharmacy. Pt discharged at 1830. A second set of vitals were taken prior to patient's discharge. All WNL.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Chest pain
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- Viral illness not COVID
- Vorgeschichte
- Tachycardia Palpitations POTS Hyperlipidemia PCOS Major depressive disorder Obesity
- Andere Medikamente
- Zyrtec, Slynd, Flonase, multivitamin, Nicorette lozenge, Omeprazole, ADIPEX-P, propranolol, Mucinex
- Allergien
- Latex Grapefruit extract
- Vorherige Impfungen
- -
- Staat
- MI
- Alter
- 55,0
- Geschlecht
- M
- Eingang
- 16.05.2022
- Impfdatum
- 21.01.2022
- Beginn
- 05.05.2022
- Tage bis Beginn
- 104,0
- Dosis
- 2
- Route/Site
- IM / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: ja
Disable: unbekannt
ER: unbekannt
Erholt: ja
Abdominal cavity drainage
Adult failure to thrive
Ammonia increased
Anaemia
Ascites
Asthenia
Bicytopenia
Blood bilirubin increased
COVID-19
Condition aggravated
Culture urine positive
Dehydration
Enterococcus test positive
Haemoglobin decreased
Hepatic cirrhosis
Hepatic failure
Hypokalaemia
Hypomagnesaemia
Symptomtext
Discharge Provider: MD Primary Care Provider: PA Admission Date: 5/5/2022 Discharge Date: May 10, 2022 PRESENTING PROBLEM: Dehydration [E86.0] Failure to thrive in adult [R62.7] Bicytopenia [D75.89] Hepatic cirrhosis, unspecified hepatic cirrhosis type, unspecified whether ascites present [K74.60] COVID-19 [U07.1] HOSPITAL COURSE: This is a 55-year-old male with a history of chronic alcohol abuse who presented to the emergency room with a 5 day history of weakness and malaise. He was found to have COVID-19 without respiratory component, liver failure with a bilirubin of 5.9, hypo magnesemia, hypokalemia, anemia with a hemoglobin of 7.9 right lower lobe pneumonia, urinary tract infection with findings of Enterococcus in the on urine culture, and an elevated ammonia level of 57. Abdominal imaging demonstrated large volume ascites and he had an ultrasound-guided paracentesis prior to discharge of 1.9 L. he did not demonstrate alcohol withdrawal throughout his hospitalization but was monitored for that possibility. He was substantially improved by discharge was felt to be stable to discharge to home.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Condition aggravated
- Hospital-Tage
- 5,0
- Labordaten
- -
- Aktuelle Erkrankungen
- 1/2/2022 ED Visit to Hospital 1. Idiopathic acute pancreatitis, unspecified complication status 2. Jaundice due to hepatitis 3. Thrombocytopenia 4. Chronic anemia 5. Elevated bilirubin Discharge Provider: MD Primary Care Provider at Discharge: DO Admission Date: 12/24/2021 Discharge Date: 12/29/2021 DIAGNOSIS at time of disposition: 1. Acute pancreatitis, unspecified complication status, unspecified pancreatitis type 2. Thrombocytopenia 3. Chronic liver disease and cirrhosis 4. Hypocalcemia Discharge Provider: MD Primary Care Provider at Discharge: DO Admission Date: 12/17/2021 Discharge Date: 12/21/2021 PRESENTING PROBLEM: GI bleed [K92.2] 1. Acute liver failure without hepatic coma 2. Thrombocytopenia 3. Gingival bleeding 4. Acute blood loss anemia 5. Esophageal varices in alcoholic cirrhosis 6. Acute upper GI bleed
- Vorgeschichte
- Portal hypertension HTN (hypertension) Hyperlipidemia LDL goal < 130 Fatty liver History of prostate cancer Cervical disc displacement Hearing loss, unspecified hearing loss type, unspecified laterality Anemia, unspecified type GERD (gastroesophageal reflux disease) OSA (obstructive sleep apnea), severe Erectile dysfunction due to diseases classified elsewhere Prostate cancer Congenital contracture of left gastrocnemius muscle Congenital contracture of right gastrocnemius muscle Plantar fasciitis of left foot Plantar fasciitis of right foot Alcohol use disorder, moderate, dependence Closed right hip fracture, initial encounter Bicytopenia Acute blood loss anemia Cirrhosis of liver with ascites Moderate protein-calorie malnutrition Psoriasis
- Andere Medikamente
- adalimumab CF (HUMIRA) 40 MG/0.4ML prefilled pen amoxicillin (AMOXIL) 875 MG tablet (Expired) atenolol (TENORMIN) 100 MG tablet desvenlafaxine (PRISTIQ) 100 MG 24 hr tablet furosemide (LASIX) 40 MG tablet lactulose (CONSTULOSE) 20 GM/3
- Allergien
- Lisinopril-Angioedema
- Vorherige Impfungen
- -
- Staat
- KY
- Alter
- 26,0
- Geschlecht
- F
- Eingang
- 13.05.2022
- Impfdatum
- 13.05.2022
- Beginn
- 13.05.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Amnesia
Blood glucose normal
Dyspnoea
Fall
Muscle rigidity
Oxygen saturation decreased
Unresponsive to stimuli
Symptomtext
Patient received the hepatitis B vaccine first in the left arm, and was stable, after that she was given the hepatitis A vaccine in the right arm. Patient was alert and oriented speaking to the provider, when the provider noticed the patient was falling off of the exam table. Provider was able to catch patients head before it hit the floor. Patient then became very rigid, and had a gasping like sound when breathing. Patients O2 saturation dropped to 80% on RA, and patient was not alert at the time. about 3 minutes after patient had fallen to the floor she came to, and sat up on the floor where she was laying. O2 Saturation was still in the low 80's%. Provider called EMS, who checked patients glucose which was 108. Once patient was stabilized she became alert and oriented x 4, she did not have memory of what happened before waking up on the floor. Her heart rates was 91-110 bpm, and her O2 saturation did stabilize at 99% o n RA.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dyspnoea
- Hospital-Tage
- -
- Labordaten
- glucose 108 heart rate 91-110bpm O2 saturation 80%-99% on RA
- Aktuelle Erkrankungen
- NA
- Vorgeschichte
- hypothyroidism
- Andere Medikamente
- Levothyroxine last dose last night
- Allergien
- NA
- Vorherige Impfungen
- -
- Staat
- CO
- Alter
- 37,0
- Geschlecht
- F
- Eingang
- 15.02.2022
- Impfdatum
- 15.02.2022
- Beginn
- 15.02.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Feeling hot
Hypoaesthesia
Paraesthesia
Paraesthesia oral
Pruritus
Symptomtext
Numbness and tingling in fingers and toes, tingling in mouth and mouth feeling hot, itching on trunk
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Paraesthesia
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- None
- Andere Medikamente
- PPD TUBERSOL
- Allergien
- History of reaction to pertussis vaccine in the past but requesting TDAP today anyways.
- Vorherige Impfungen
- -
- Staat
- -
- Alter
- 44,0
- Geschlecht
- F
- Eingang
- 10.03.2022
- Impfdatum
- 09.03.2022
- Beginn
- 10.03.2022
- Tage bis Beginn
- 1,0
- Dosis
- 2
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Arthralgia
Injection site discomfort
Product administered at inappropriate site
Symptomtext
Injected too close to the shoulder, sore shoulder (not at injection site), felt discomfort upon administration
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Arthralgia
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- -
- Alter
- 37,0
- Geschlecht
- M
- Eingang
- 21.12.2021
- Impfdatum
- 17.12.2021
- Beginn
- 17.12.2021
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Erythema
Pruritus
Rash
Symptomtext
Approximately 2 hours after receiving Hep B vaccine booster, patient reported that he started to experience itching, mainly on both elbow and neck with accompanied reddish spots. Spots had deepened and bulged with worsened itching by night time. Patient applied OTC hydrocortisone cream, 1%. The following day the sports reduced but was still experiencing mild but spontaneous spots with rash and itching that would erupt.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Pruritus
- Hospital-Tage
- -
- Labordaten
- none
- Aktuelle Erkrankungen
- No illness known. Received COVID vaccine booster on 12/5/2021
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- none known
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 31,0
- Geschlecht
- F
- Eingang
- 23.09.2021
- Impfdatum
- 20.09.2021
- Beginn
- 22.09.2021
- Tage bis Beginn
- 2,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Dizziness
Feeling abnormal
Headache
Symptomtext
Patient complaint of dizziness, headaches, and feeling off. Symptoms started 09/22/2021
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Dizziness
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- none
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- ME
- Alter
- 48,0
- Geschlecht
- M
- Eingang
- 13.09.2021
- Impfdatum
- 07.09.2021
- Beginn
- 07.09.2021
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Chills
Eye pain
Headache
Hyperhidrosis
Pain
Rash
Symptomtext
Patent called stating on 9/7/2021 afternoon began having body aches. Woke the next day with headache and eyes hurt rash on arms and belly, sweats and chills. Unsure if he has a fever. Today 9/9/2021 rash is gone but continues with headache and eyes hurt, especially if he turns his head or coughs. States does not feel as though he is sick with a cough, though Taking tylenol with some relief No difficulty breathing or swelling. patient did not have any symptoms with previous two vaccines. Plan is to monitor over the next 24 hours if symptoms worsen or do not improve be seen by pcp or urgent care.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Chills
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MN
- Alter
- 38,0
- Geschlecht
- F
- Eingang
- 26.08.2021
- Impfdatum
- 19.08.2021
- Beginn
- 19.08.2021
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- SYR / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Headache
Pyrexia
SARS-CoV-2 test negative
Symptomtext
Having intermittent headaches with fever since receiving
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Headache
- Hospital-Tage
- -
- Labordaten
- Reports had covid test that was negative
- Aktuelle Erkrankungen
- Tested covid negative
- Vorgeschichte
- unknown
- Andere Medikamente
- Vitamin
- Allergien
- Unknown
- Vorherige Impfungen
- -
- Staat
- PR
- Alter
- 44,0
- Geschlecht
- M
- Eingang
- 24.08.2021
- Impfdatum
- 17.05.2021
- Beginn
- 18.05.2021
- Tage bis Beginn
- 1,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Arthralgia
Asthenia
Dizziness
Fatigue
Injection site pain
Oropharyngeal pain
Pain in extremity
Symptomtext
Tiredness all the time, lost of strength in arms and legs, pain in all articulations (hands, shoulders, knees, ankles) dizziness every now and then, a sensation of burning in the site of injection that comes and goes, sore throat the first two weeks. But the most unlikely effect is the constant tiredness and weakness and arthritis like feeling in upper and lower extremities. At first I though is will be a week or two, but now is almost three months and it continues.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Arthralgia
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- No
- Vorgeschichte
- No
- Andere Medikamente
- Omega 3 (fish Oil) sporadically-not daily, and B-complex vitamins.
- Allergien
- No
- Vorherige Impfungen
- -
- Staat
- IN
- Alter
- 51,0
- Geschlecht
- F
- Eingang
- 15.07.2021
- Impfdatum
- 17.06.2021
- Beginn
- 07.07.2021
- Tage bis Beginn
- 20,0
- Dosis
- 4
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: ja
Disable: unbekannt
ER: unbekannt
Erholt: nein
Full blood count
Haematocrit normal
Haemoglobin normal
Laboratory test
Mean cell haemoglobin concentration normal
Mean cell haemoglobin normal
Mean cell volume normal
Platelet count decreased
Rash
Red blood cell count normal
Red cell distribution width normal
White blood cell count normal
Symptomtext
Pt noted a rash on 7/7/2021 and got worse by 7/9/2021. Pt reports going to Urgent Care and labs were drawn noting she had low platelets. Pt was sent to the ER and more labs were drawn and at this point platelet count was at zero. Pt was kept in the hospital for two days. Pt is currently taking a tapered dose of prednisone. Pt still has light rash and will be seeing her family doctor today 7/14/201 and a Hematologist on 7/19/2021.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Rash
- Hospital-Tage
- 2,0
- Labordaten
- 7/9/2021 - Complete Blood Count WBC 7.2 10*3/uL Red Blood Cell 4.45 10*6/uL Hemoglobin 13.4 g/dl Hematocrit 39.5% MCV 88.7 fl MCH 30.0 pg MCHC 33.8 g/dL RDW 12.7% Platelet 0 10.3/uL
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- Hx of Breast Cancer 25 years ago Hx of Migraines
- Andere Medikamente
- Amitriptyline 25 Mg Imitrex 100 mg Propranolol 80 mg
- Allergien
- Pencillin
- Vorherige Impfungen
- -
- Staat
- CO
- Alter
- 29,0
- Geschlecht
- M
- Eingang
- 28.04.2023
- Impfdatum
- 19.04.2023
- Beginn
- 19.04.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Expired product administered
Symptomtext
Expired dose was given by accident; This non-serious case was reported by a physician via call center representative and described the occurrence of expired vaccine used in a 29-year-old male patient who received HBV (Engerix B) (batch number N4GA4, expiry date 02-JAN-2023) for prophylaxis. On 19-APR-2023, the patient received the 1st dose of Engerix B. On 19-APR-2023, an unknown time after receiving Engerix B, the patient experienced expired vaccine used (Verbatim: Expired dose was given by accident). The outcome of the expired vaccine used was unknown. Additional Information: GSK Receipt Date: 19-APR-2023 A physician wanted to know how to proceed further. Information about the patient and vaccine were given. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. The patient accidently expired dose of Engerix B, which led to expired vaccine used.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MO
- Alter
- 68,0
- Geschlecht
- M
- Eingang
- 03.03.2023
- Impfdatum
- 21.02.2023
- Beginn
- 21.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Expired product administered
Symptomtext
Expired Engerix administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 68-year-old male patient who received HBV (Engerix B) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. On 21st February 2023, the patient received Engerix B. On 21st February 2023, unknown after receiving Engerix B, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. Additional Information: GSK Receipt Date: 21-Feb-2023 Reporter's comment: The medical assistant called to enquire if patient should be revaccinate as they inadvertently administered an expired Engerix dose to a patient in their facility. The reporter did not consent to follow up. Additional Supportive Information: The patient received an expired dose of Engerix, which led to expired vaccine used.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- TX
- Alter
- -
- Geschlecht
- U
- Eingang
- 10.02.2023
- Impfdatum
- 07.02.2023
- Beginn
- 07.02.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Expired product administered
Symptomtext
Expired Engerix administered; This case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a patient who received HBV (Engerix B) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 7th February 2023, the patient received Engerix B and Engerix B Pre-Filled Syringe Device. On 7th February 2023, unknown after receiving Engerix B and Engerix B Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-FEB-2023 Reporter's Comment: The pharmacist reported that a nurse inadvertently administered an expired dose of Engerix-B. The additional patient information was not known. The reporter consent to follow up via email. Additional Supportive Information: The patient received an expired dose of Engerix B, which led to expired vaccine used.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MD
- Alter
- 23,0
- Geschlecht
- F
- Eingang
- 26.01.2023
- Impfdatum
- 13.01.2023
- Beginn
- 13.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Expired product administered
Symptomtext
Expired Engerix B administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 23-year-old female patient who received HBV (Engerix B) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. On 13th January 2023, the patient received the 1st dose of Engerix B. On 13th January 2023, unknown after receiving Engerix B, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. Additional Information: GSK receipt date: 17-Jan-2023 Reporter's comment: Office staff member reported that a medical assistant administered a dose of Engerix-B vaccine which had an expired. This was the patient's first dose in the series. At the time of reporting, the dose had not been repeated. The reporter gave permission for follow-up. Additional supportive information: The patient received an expired dose of Engerix-B, which led to expired vaccine used.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MI
- Alter
- 13,0
- Geschlecht
- F
- Eingang
- 23.01.2023
- Impfdatum
- 06.10.2022
- Beginn
- 06.10.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Unevaluable event
Symptomtext
No signs, or symptoms noted.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Unevaluable event
- Hospital-Tage
- -
- Labordaten
- None
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- NJ
- Alter
- 37,0
- Geschlecht
- F
- Eingang
- 19.01.2023
- Impfdatum
- 19.01.2023
- Beginn
- 19.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
Expired product administered
Symptomtext
Patient given 2n dose of Energix-B, Vaccine was 17 dyas expired. Patient contacted by telephone and advised of the event. She denied any ill effects.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- OH
- Alter
- 41,0
- Geschlecht
- M
- Eingang
- 13.01.2023
- Impfdatum
- 03.01.2023
- Beginn
- 03.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Expired product administered
Serology negative
Symptomtext
Expired Engerix B administered; 1st dose on 18Sep2021, 2nd on 03Jan2023; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 41-year-old male patient who received HBV (Engerix B) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. Previously administered products included Engerix B (On 18th September 2021, received 1st dose). On 3rd January 2023, the patient received the 2nd dose of Engerix B. On 3rd January 2023, unknown after receiving Engerix B, the patient experienced expired vaccine used and drug dose administration interval too long. On an unknown date, the outcome of the expired vaccine used and drug dose administration interval too long were unknown. Additional Information: GSK Receipt date: 03-Jan-2023. Reporter's Comment: The patient never went back for second dose. Titers were collected which were negative, so the patient was restarting the series today (on the day of reporting). At the time of reporting, a repeat dose had not been given following the expired dose. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow- up. Additional Supportive Information: Patient received dose of Engerix-B of expired date, which led to expired vaccine used. Patient received 2nd dose of Engerix-B late, which led to drug dose administration interval too long.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- Test Name: Serology; Result Unstructured Data: (Test Result:Titres were negative,Unit:unknown,Normal Low:,Normal High:)
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MI
- Alter
- 77,0
- Geschlecht
- M
- Eingang
- 12.01.2023
- Impfdatum
- 03.01.2023
- Beginn
- 03.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Expired product administered
Symptomtext
Expired Engerix administered; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 77-year-old male patient who received HBV (Engerix B adult) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. On 3rd January 2023, the patient received Engerix B adult and Engerix B Pre-Filled Syringe Device. On 3rd January 2023, unknown after receiving Engerix B adult and Engerix B Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 05 JAN 2023 Reporters comment: The nurse practitioner reported that the patient received an adult dose of Engerix B on 3rd January 2023 and the dose had expired on 2nd January 2023. The reporter wanted to know should re vaccinate. The Vaccine Administration Facility was the same as Primary Reporter. Additional supportive information. As patient administered expired vaccine which led to expired vaccine used. Reporter did not consent to follow up as no contact details were available.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- MI
- Alter
- 77,0
- Geschlecht
- M
- Eingang
- 05.01.2023
- Impfdatum
- 03.01.2023
- Beginn
- 03.01.2023
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Expired product administered
No adverse event
Symptomtext
Patient was given an adult Hepatitis B vaccine on 01/03/2023; however, the vaccine had an expiration date of 01/02/2023.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Expired product administered
- Hospital-Tage
- -
- Labordaten
- None; patient was called on 01/05/2023 after error was noticed and stated he was not experiencing any side effects or symptoms after having received vaccines.
- Aktuelle Erkrankungen
- None
- Vorgeschichte
- Hypertension and Hyperlipidemia
- Andere Medikamente
- -Lisinopril 5 mg TID -Norvasc 5 mg daily -Atenolol 25 at bedtime -Atorvastatin 20 mg at bedtime
- Allergien
- None
- Vorherige Impfungen
- -
- Staat
- NC
- Alter
- 63,0
- Geschlecht
- F
- Eingang
- 04.08.2022
- Impfdatum
- 13.06.2022
- Beginn
- 13.06.2022
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product administered to patient of inappropriate age
Wrong product administered
Symptomtext
received Pediarix instead of Engerix-B; 63 year-old received Pediarix; This case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 63-year-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. Co-suspect products included dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis. Previously administered products included Engerix B (received 1st dose in December 2021) and Engerix B (received 2nd dose on 17th January 2022). On 13th June 2022, the patient received Pediarix and Pediarix Pre-Filled Syringe Device. On 13th June 2022, unknown after receiving Pediarix and Pediarix Pre-Filled Syringe Device, the patient experienced wrong vaccine administered and inappropriate age at vaccine administration. On an unknown date, the outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 01-Aug-2022 Reporter's comment: The patient received Pediarix vaccine instead of Engerix-B third dose. The reporter consented to follow-up. Additional supportive information: The patient received Pediarix vaccine instead of third dose of Engerix-B, which led to wrong vaccine administered and inappropriate age at vaccine administration.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product administered to patient of inappropriate age
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- OH
- Alter
- 19,0
- Geschlecht
- F
- Eingang
- 01.07.2022
- Impfdatum
- 12.05.2022
- Beginn
- 12.05.2022
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: unbekannt
No adverse event
Product administered to patient of inappropriate age
Symptomtext
No adverse reaction at this time. Age 19 when admin Engerix B 20+ yrs old
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- No adverse event
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- unknown
- Vorgeschichte
- unknown
- Andere Medikamente
- unknown
- Allergien
- NKDA
- Vorherige Impfungen
- -
- Staat
- TX
- Alter
- -
- Geschlecht
- U
- Eingang
- 17.05.2022
- Impfdatum
- 03.05.2022
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product storage error
Symptomtext
Engerix B below recommended temperature, administered; This case was reported by a other health professional via call center representative and described the occurrence of incorrect product storage in a patient who received HBV (Engerix B) (batch number N4GA4, expiry date unknown) for prophylaxis. On 3rd May 2022, the patient received Engerix B. On an unknown date, unknown after receiving Engerix B, the patient experienced incorrect product storage. On an unknown date, the outcome of the incorrect product storage was unknown. Additional Information: GSK Receipt Date: 11-May-2022 Reporter's comments: Engerix-B vaccines went below recommended temperature range on 21st March 2022. The lowest temperature was 30.2F. The readings were then ranging from 32.9F to 41.8F. The duration was 7 hr. 45 min. A dose was subsequently administered. The reporter did not have expiration date, or patient information aside from initials. Till the time of reporting, a repeat dose had not been administered. The reporter consented to follow up. Additional Supportive Information: The patient received incorrectly stored vaccine, which led to product storage error; Sender's Comments: US-GLAXOSMITHKLINE-US2022077006:Same reporter US-GLAXOSMITHKLINE-US2022077007:Same reporter US-GLAXOSMITHKLINE-US2022077008:Same reporter US-GLAXOSMITHKLINE-US2022077005:Same reporter
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product storage error
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- OH
- Alter
- 19,0
- Geschlecht
- F
- Eingang
- 29.01.2022
- Impfdatum
- 30.08.2021
- Beginn
- 29.01.2022
- Tage bis Beginn
- 152,0
- Dosis
- 2
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Hepatitis B antibody negative
Incorrect dose administered
No adverse event
Symptomtext
On 8/30/2021 Patient presented to store for encounter for immunization for hepatitis B vaccine 2/3. She received Recombivax peds/adol on 7/29/21 at a different Store. Store did not have Recombivax in stock, so it was decided to administer Energix-B. The patient, age 19, was given the adult dose of Energix-B, 1 mL, lot # N4GA4. She was advised to receive her third dose of the series at the end of January. Today, 1/29/2022, she presented to store for her third dose of the hepatitis vaccine, but it was realized that she was given the adult dose in 08/2021 instead of the pediatric dose of Energix-B. Hep B antibody titers were drawn today and no vaccine was administered. Patient reported no adverse reactions or side effects of the adult dose of Energix-B after administration in 08/2021. Clinic manager and Clinic Practice Coordinator were notified.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Hepatitis B antibody negative
- Hospital-Tage
- -
- Labordaten
- N/A
- Aktuelle Erkrankungen
- N/A
- Vorgeschichte
- N/A
- Andere Medikamente
- unknown
- Allergien
- NKA
- Vorherige Impfungen
- -
- Staat
- IA
- Alter
- 19,0
- Geschlecht
- M
- Eingang
- 10.12.2021
- Impfdatum
- 25.08.2021
- Beginn
- 25.08.2021
- Tage bis Beginn
- 0,0
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Overdose
Product administered to patient of inappropriate age
Symptomtext
This case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 19-year-old male patient who received HBV (Engerix B adult) (batch number n4ga4, expiry date 2nd January 2023) for prophylaxis. Co-suspect products included HBV (Engerix B adult) (batch number n4ga4, expiry date 2nd January 2023) for prophylaxis. On 29th September 2021, the patient received Engerix B adult. On 25th August 2021, the patient received Engerix B adult. On 25th August 2021, not applicable after receiving Engerix B adult and unknown after receiving Engerix B adult, the patient experienced inappropriate age at vaccine administration and overdose. On 29th September 2021, the patient experienced inappropriate age at vaccine administration and overdose. On an unknown date, the outcome of the inappropriate age at vaccine administration, overdose, inappropriate age at vaccine administration and overdose were unknown. Additional details were reported as follows: The reporter reported that a patient of 19 years received two doses of Engerix B adult vaccine, which led to inappropriate age of vaccine administration and overdose. The reporter consented to follow up.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Overdose
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- CO
- Alter
- -
- Geschlecht
- F
- Eingang
- 23.11.2021
- Impfdatum
- 27.10.2021
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product storage error
Symptomtext
Error storage for Engerix-B given to a patient; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a female patient who received HBV (Engerix B) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. On 27th October 2021, the patient received Engerix B. On an unknown date, unknown after receiving Engerix B, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. Additional details were provided as follows: The age at vaccination was not reported. The practice manager called to report that Engerix-B was administered to patient after a temperature excursion, which led to incorrect storage of drug. This lot number was exposed to a lowest temperature of 18 degree Fahrenheit for more than 30 days, vaccines are not longer viable. The reporter consented to follow up. This case was linked with case US2021237516, reported by same reporter for different patient.; Sender's Comments: US-GLAXOSMITHKLINE-US2021237516:Same reporter. Pt 1/2
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product storage error
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- CO
- Alter
- -
- Geschlecht
- M
- Eingang
- 23.11.2021
- Impfdatum
- 04.11.2021
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- UNK
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Product storage error
Symptomtext
Error storage for Engerix-B given to a patient; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a male patient who received HBV (Engerix B) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. On 4th November 2021, the patient received Engerix B. On an unknown date, unknown after receiving Engerix B, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. Additional details were provided as follows: The age at vaccination was not reported. The practice manager called to report that Engerix-B was administered to patient after a temperature excursion, which led to incorrect storage of drug. This lot number was exposed to a lowest temperature of 18 degree Fahrenheit for more than 30 days, vaccines are not longer viable. The reporter consented to follow up. This case was linked with case US2021237518, reported by same reporter for different patient.; Sender's Comments: US-GLAXOSMITHKLINE-US2021237518:Same reporter. Pt 2/2
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Product storage error
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- WA
- Alter
- -
- Geschlecht
- F
- Eingang
- 15.10.2021
- Impfdatum
- 01.05.2021
- Beginn
- 01.05.2021
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Inappropriate schedule of product administration
Symptomtext
late second dose and a late third dose; late second dose and a late third dose; This case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 30-year-old female patient who received HBV (Engerix B) (batch number N4GA4, expiry date unknown) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (received 1st dose on September 2020). In October 2021, the patient received the 3rd dose of Engerix B. In May 2021, the patient received the 2nd dose of Engerix B. In May 2021, not applicable after receiving Engerix B and unknown after receiving Engerix B, the patient experienced drug dose administration interval too long. In October 2021, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long and drug dose administration interval too long were unknown. Additional details were provided as follows: The age at vaccination was not reported. The patient had been given a late second dose and a late third dose of the Engerix-B vaccine, which led to lengthening of vaccination schedule. The reporter consented to follow.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Inappropriate schedule of product administration
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- NV
- Alter
- 19,0
- Geschlecht
- M
- Eingang
- 11.09.2021
- Impfdatum
- 11.09.2021
- Beginn
- 11.09.2021
- Tage bis Beginn
- 0,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Incorrect dose administered
Symptomtext
Provided patient with the Hepatitis B vaccination (Adult dose).
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Incorrect dose administered
- Hospital-Tage
- -
- Labordaten
- N/A
- Aktuelle Erkrankungen
- N/A
- Vorgeschichte
- N/A
- Andere Medikamente
- N/A
- Allergien
- N/A
- Vorherige Impfungen
- -
- Staat
- SD
- Alter
- 19,0
- Geschlecht
- F
- Eingang
- 24.08.2021
- Impfdatum
- -
- Beginn
- -
- Tage bis Beginn
- -
- Dosis
- 2
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Incorrect dose administered
Product administered to patient of inappropriate age
Symptomtext
19 year old patient received an adult dose of Engerix-B; 19 year old patient received an adult dose of Engerix-B; This case was reported by a other health professional via call center representative and described the occurrence of adult product administered to child in a 19-year-old female patient who received HBV (Engerix B adult) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. Previously administered products included Engerix B (1st dose received on an unknown date). On an unknown date, the patient received the 2nd dose of Engerix B adult. On an unknown date, unknown after receiving Engerix B adult, the patient experienced adult product administered to child and overdose. On an unknown date, the outcome of the adult product administered to child and overdose were unknown. Additional details were provided are as follows: A 19 years old patient received an adult dose of Engerix B in her series which led to adult product administered to child and overdose. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up via email.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Incorrect dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 36,0
- Geschlecht
- F
- Eingang
- 04.08.2021
- Impfdatum
- 14.07.2021
- Beginn
- 14.07.2021
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Exercise tolerance decreased
Joint range of motion decreased
Nerve injury
Symptomtext
Difficult time with full range of motion, difficult to lift items over 10 LBS, Feels like a nerve is affected. Unable to do curtain exercises at local gym. It has not gone away since 07/14/2021. Will be seeking advise from a Primary Care provider.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Exercise tolerance decreased
- Hospital-Tage
- -
- Labordaten
- None.
- Aktuelle Erkrankungen
- None indicated
- Vorgeschichte
- None indicated
- Andere Medikamente
- None indicated
- Allergien
- None indicated
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 20,0
- Geschlecht
- M
- Eingang
- 31.07.2021
- Impfdatum
- 21.07.2021
- Beginn
- 27.07.2021
- Tage bis Beginn
- 6,0
- Dosis
- 3
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: ja
Asthenia
Computerised tomogram head normal
Electrocardiogram normal
Impaired driving ability
Laboratory test normal
Road traffic accident
Symptomtext
15 minutes after injection, felt weak while driving. woke up and saw he had crashed car
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Asthenia
- Hospital-Tage
- -
- Labordaten
- lab normal. ct head - no bleed. possible pineal cyst. ekg normal
- Aktuelle Erkrankungen
- none
- Vorgeschichte
- diabetes type 1
- Andere Medikamente
- humalog , lipitor
- Allergien
- none
- Vorherige Impfungen
- -
- Staat
- TX
- Alter
- -
- Geschlecht
- F
- Eingang
- 17.07.2021
- Impfdatum
- 12.07.2021
- Beginn
- 12.07.2021
- Tage bis Beginn
- 0,0
- Dosis
- 4
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Extra dose administered
Symptomtext
in adverted administration of a 4th dose of Engerix-B; was supposed to be receiving the last dose of Havrix; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 61-year-old female patient who received HBV (Engerix B) (batch number n4ga4, expiry date 2nd January 2023) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. Previously administered products included Engerix B (received first 3 doses of Engerix B on an unknown date). On 12th July 2021, the patient received the 4th dose of Engerix B and Engerix B Pre-Filled Syringe Device. On 12th July 2021, unknown after receiving Engerix B and Engerix B Pre-Filled Syringe Device, the patient experienced extra dose administered and wrong vaccine administered. On an unknown date, the outcome of the extra dose administered and wrong vaccine administered were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The age at the vaccination was not reported. The nurse reported that, the patient was supposed to be receiving the last dose of Havrix but received in adverted administration of 4th dose of Engerix-B, which led to extra dose administered and wrong vaccine administered. No further events were reported. The health care professional agreed on follow-up.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- ENGERIX B Pre-Filled Syringe Device
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- AL
- Alter
- 31,0
- Geschlecht
- F
- Eingang
- 24.06.2021
- Impfdatum
- 09.06.2021
- Beginn
- 19.06.2021
- Tage bis Beginn
- 10,0
- Dosis
- UNK
- Route/Site
- IM / RA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Hypoaesthesia
Limb discomfort
Symptomtext
Right arm feels heavy/numb
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Hypoaesthesia
- Hospital-Tage
- -
- Labordaten
- No
- Aktuelle Erkrankungen
- N/A
- Vorgeschichte
- N/A
- Andere Medikamente
- -
- Allergien
- N/A
- Vorherige Impfungen
- -
- Staat
- IA
- Alter
- 0,1
- Geschlecht
- M
- Eingang
- 11.06.2021
- Impfdatum
- 08.10.2003
- Beginn
- 08.10.2003
- Tage bis Beginn
- 0,0
- Dosis
- 4
- Route/Site
- IM / LA
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Extra dose administered
Inappropriate schedule of product administration
Symptomtext
accidentally administered an extra dose (Extra Dose); per record, the patient received the first dose /on 08/20/2003, / and third dose on 01/2004. The schedule between 1st and 3rd dose was one month early. (Inappropriate schedule of vaccine).; per record, the patient received the first dose / on 08/20/2003, second dose on 10/08/2003; This case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 1-month-old male patient who received HBV (Engerix B) (batch number N4GA4, expiry date unknown) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis, Hepatitis B vaccine for prophylaxis and Hepatitis B vaccine for prophylaxis. Previously administered products included Hepatitis b vaccine (1st dose received on 20th August 2003). On 7th June 2021, the patient received the 4th dose of Engerix B (intramuscular) .5 ml and Engerix B Pre-Filled Syringe Device. In January 2004, the patient received the 3rd dose of Hepatitis B vaccine. On 8th October 2003, the patient received the 2nd dose of Hepatitis B vaccine. On 8th October 2003, not applicable after receiving Engerix B, Engerix B Pre-Filled Syringe Device and Hepatitis B vaccine and unknown after receiving Hepatitis B vaccine, the patient experienced drug dose administration interval too long. In January 2004, the patient experienced drug dose administration interval too short. On 7th June 2021, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered, drug dose administration interval too long and drug dose administration interval too short were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The patient accidentally received dose of Engerix B which led extra dose administered. The patient received 2nd dose of Hepatitis B vaccine, more than recommended interval which led lengthening of vaccinaton schedule. The patient received 3rd dose of Hepatitis B vaccine, less than the recommended interval which led to shortening of vaccination. The reporter consented to follow up via email. This case was linked with case US2021122659 reported by the same reporter; Sender's Comments: US-GLAXOSMITHKLINE-US2021122659:Same Reporter
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- TN
- Alter
- 17,0
- Geschlecht
- F
- Eingang
- 11.06.2021
- Impfdatum
- 08.06.2021
- Beginn
- 08.06.2021
- Tage bis Beginn
- 0,0
- Dosis
- 2
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Extra dose administered
Product administered to patient of inappropriate age
Symptomtext
a 17 year old / received an adult dose of Engerix-B; a 17 year old / received an adult dose of Engerix-B; This case was reported by a nurse via call center representative and described the occurrence of overdose in a 17-year-old female patient who received HBV (Engerix B adult) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. Co-suspect products included hepatitis B vaccine pre-filled syringe device (Engerix B Pre-Filled Syringe Device) injection syringe for prophylaxis. Previously administered products included Engerix B (1st dose received on an unknown date). On 8th June 2021, the patient received the 2nd dose of Engerix B adult and Engerix B Pre-Filled Syringe Device. On 8th June 2021, unknown after receiving Engerix B adult and Engerix B Pre-Filled Syringe Device, the patient experienced overdose and inappropriate age at vaccine administration. On an unknown date, the outcome of the overdose and inappropriate age at vaccine administration were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: Nurse reported that a 17 year old patient who received an adult dose of Engerix-B, it was administered on the same day as reported it which led to overdose and inappropriate age at vaccine administration. The reporter consented to follow up.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -
- Staat
- CA
- Alter
- 19,0
- Geschlecht
- F
- Eingang
- 19.05.2021
- Impfdatum
- 19.03.2021
- Beginn
- 19.03.2021
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- - / -
Tod: unbekannt
Lebensbedrohlich: unbekannt
Hospital: unbekannt
Disable: unbekannt
ER: unbekannt
Erholt: nein
Incorrect dose administered
Symptomtext
given a 20 mcg/mL dose of Engerix-B to a 19 year old patient; given a 20 mcg/mL dose of Engerix-B to a 19 year old patient; This case was reported by a pharmacist via call center representative and described the occurrence of overdose in a 19-year-old female patient who received HBV (Engerix B adult) (batch number N4GA4, expiry date 2nd January 2023) for prophylaxis. On 19th March 2021, the patient received the 1st dose of Engerix B adult. On 19th March 2021, unknown after receiving Engerix B adult, the patient experienced overdose and adult product administered to child. On an unknown date, the outcome of the overdose and adult product administered to child were unknown. Additional details were provided as follows: The patient had been given a 20 mcg/mL dose of Engerix B, which led to overdose and adult product administered to child. The reporter consented to follow up. For the tolerance of 2nd dose, refer case- US2021AMR103721, reported by the same reporter.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Incorrect dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -